LncRNA XIST promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by downregulating miR-27b-3p

S. Q. Ma; Y. C. Wang; Y. Li; X. Y. Li; J. Yang; Y. M. Sheng

doi:10.23812/20-222-A

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

LncRNA XIST promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by downregulating miR-27b-3p

S. Q. Ma, Y. C. Wang, Y. Li, X. Y. Li, J. Yang, Y. M. Sheng

Article ID: 4912
Vol 34, Issue 6, 2020

DOI: https://doi.org/10.23812/20-222-A

Received: 8 January 2021; Accepted: 8 January 2021; Available online: 8 January 2021; Issue release: 8 January 2021

Abstract

Chemotherapy resistance has become a major obstacle to effective treatment of human cancer. This study aimed to investigate the effect of lncRNA XIST on cell proliferation and cisplatin (CDDP) of oral squamous cell carcinoma (OSCC). RT-qPCR and Western blot analysis were used to detect mRNA and protein expression. CCK-8 and ﬂow cytometry assays were explored to evaluate CDDP sensitivity in OSCC cells. The relationship between lncRNA XIST and miR-27b-3p was confirmed by luciferase reporter assay. The results showed that lncRNA XIST was upregulated in OSCC tissues, cell lines, and CDDP-resistant OSCC cells. Functionally, upregulation of lncRNA XIST promoted cell proliferation, enhanced CDDP resistance, and inhibited apoptosis in OSCC cells. In addition, lncRNA XIST acts as a molecular sponge for miR-27b-3p in OSCC. Downregulation of miR-27b-3p partially reversed the tumor suppression effect and CDDP chemosensitivity of XIST knockdown in CDDP-resistant OSCC cells. In conclusion, lncRNA XIST promotes cell proliferation and enhances resistance to CDDP in OSCC by downregulating miR-27b-3p.

Keywords

LncRNA XIST;cisplatin;proliferation;oral squamous cell carcinoma;miR-27b-3p

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...